Publicação

Consensus for the Early Identification of Secondary Progressive Multiple Sclerosis in Portugal: a Delphi Panel

Ver documento

Detalhes bibliográficos
Resumo:Introduction: Multiple sclerosis is a disease with a heterogeneous evolution. The early identification of secondary progressive multiple sclerosis is a clinical challenge, which would benefit from the definition of biomarkers and diagnostic tools applicable in the transition phase from relapsing-remitting multiple sclerosis to secondary progressive multiple sclerosis. We aimed to reach a Portuguese national consensus on the monitoring of patients with multiple sclerosis and on the more relevant clinical variables for the early identification of its progression.Material and Methods: A Delphi panel which included eleven Portuguese Neurologists participated in two rounds of questions between July and August of 2021. In the first round, 39 questions which belonged to the functional, cognitive, imaging, biomarkers and additional evaluations were included. Questions for which no consensus was obtained in the first round (less than 80% of agreement), were appraised by the panel during the second round. Results: The response rate was 100% in both rounds and consensus was reached for a total of 33 questions (84.6%). Consensus was reached for monitoring time, evaluation scales and clinical variables such as the degree of brain atrophy and mobility reduction, changes suggestive of secondary progressive multiple sclerosis. Additionally, digital devices were considered tools with potential to identify disease progression. Most questions for which no consensus was obtained referred to the cognitive assessment and the remaining referred to both functional and imaging domains.Conclusion: Consensus was obtained for the determination of the monitorization interval and for most of the clinical variables. Most questions that did not reach consensus were related with the confirmation of progression taking into account only one test/domain, reinforcing the multifactorial nature of multiple sclerosis.
Autores principais:Sá, Maria José
Outros Autores:Basílio, Carlos; Capela, Carlos; Cerqueira, José João; Mendes, Irene; Morganho, Armando; Correia de Sá, João; Salgado, Vasco; Martins Silva, Ana; Vale, José; Sousa, Lívia
Assunto:Consensus Multiple Sclerosis, Chronic Progressive/diagnosis Portugal Consenso Esclerose Múltipla Crónica Progressiva/diagnóstico Portugal
Ano:2023
País:Portugal
Tipo de documento:artigo
Tipo de acesso:unknown
Instituição associada:Ordem dos Médicos
Idioma:inglês
Origem:Acta Médica Portuguesa
_version_ 1865920039660552192
author Sá, Maria José
author2 Basílio, Carlos
Capela, Carlos
Cerqueira, José João
Mendes, Irene
Morganho, Armando
Correia de Sá, João
Salgado, Vasco
Martins Silva, Ana
Vale, José
Sousa, Lívia
author2_role author
author
author
author
author
author
author
author
author
author
author_facet Sá, Maria José
Sá, Maria José
Basílio, Carlos
Capela, Carlos
Cerqueira, José João
Mendes, Irene
Morganho, Armando
Correia de Sá, João
Salgado, Vasco
Martins Silva, Ana
Vale, José
Sousa, Lívia
Basílio, Carlos
Capela, Carlos
Cerqueira, José João
Mendes, Irene
Morganho, Armando
Correia de Sá, João
Salgado, Vasco
Martins Silva, Ana
Vale, José
Sousa, Lívia
author_role author
country_str PT
creators_json_str [{\"Person.name\":\"Sá, Maria José\"},{\"Person.name\":\"Basílio, Carlos\"},{\"Person.name\":\"Capela, Carlos\"},{\"Person.name\":\"Cerqueira, José João\"},{\"Person.name\":\"Mendes, Irene\"},{\"Person.name\":\"Morganho, Armando\"},{\"Person.name\":\"Correia de Sá, João\"},{\"Person.name\":\"Salgado, Vasco\"},{\"Person.name\":\"Martins Silva, Ana\"},{\"Person.name\":\"Vale, José\"},{\"Person.name\":\"Sousa, Lívia\"}]
datacite.creators.creator.creatorName.fl_str_mv Sá, Maria José
Basílio, Carlos
Capela, Carlos
Cerqueira, José João
Mendes, Irene
Morganho, Armando
Correia de Sá, João
Salgado, Vasco
Martins Silva, Ana
Vale, José
Sousa, Lívia
datacite.rights.fl_str_mv http://purl.org/coar/access_right/c_abf2
datacite.subjects.subject.fl_str_mv Consensus
Multiple Sclerosis, Chronic Progressive/diagnosis
Portugal
Consenso
Esclerose Múltipla Crónica Progressiva/diagnóstico
Portugal
datacite.titles.title.fl_str_mv Consensus for the Early Identification of Secondary Progressive Multiple Sclerosis in Portugal: a Delphi Panel
Consenso Português para a Identificação Precoce de Esclerose Múltipla Secundária Progressiva: Painel Delphi
dc.creator.none.fl_str_mv Sá, Maria José
Basílio, Carlos
Capela, Carlos
Cerqueira, José João
Mendes, Irene
Morganho, Armando
Correia de Sá, João
Salgado, Vasco
Martins Silva, Ana
Vale, José
Sousa, Lívia
dc.description.none.fl_str_mv Introdução: A esclerose múltipla é uma doença de evolução heterogénea. A identificação precoce da forma secundária progressiva é um desafio clínico, carecendo da definição de biomarcadores e ferramentas de diagnóstico aplicáveis na fase de transição da forma surto-remissão para a forma secundária progressiva. Este trabalho teve como objetivo estabelecer um consenso nacional português sobre a monitorização dos doentes e das variáveis clínicas mais relevantes para a identificação precoce da progressão da esclerose múltipla.Material e Métodos: Um painel Delphi constituído por 11 neurologistas portugueses respondeu a duas rondas de perguntas entre julho e agosto de 2021. Na primeira ronda foram incluídas 39 questões relacionadas com a avaliação funcional, cognitiva, imagiológica, de biomarcadores e outras, e na segunda, as questões para as quais não foi atingido consenso (menos de 80% de concordância) na primeira ronda voltaram a ser submetidas a avaliação pelo painel.Resultados: A taxa de resposta foi de 100% em ambas as rondas e 33 das 39 questões (84,6%) atingiram concordância. Foi atingido consenso relativamente ao tempo de monitorização dos doentes, às escalas de avaliação a empregar e a variáveis clínicas tais como o grau de atrofia cerebral ou redução da mobilidade, cuja alteração é sugestiva de esclerose múltipla secundária progressiva. Adicionalmente, os dispositivos digitais foram considerados ferramentas com potencial para identificar a progressão da doença. A maioria das questões para as quais não foi obtido consenso dizem respeito à avaliação cognitiva, estando as restantes inseridas nos domínios funcional e imagiológico.Conclusão: Foi obtido consenso para a determinação do intervalo de monitorização e para a maioria das variáveis clínicas. A maioria das questões sem consenso estavam relacionadas com a confirmação do diagnóstico de progressão tendo em conta apenas um teste/domínio, realçando a natureza multifatorial da esclerose múltipla.
dc.format.none.fl_str_mv application/pdf
application/pdf
dc.identifier.none.fl_str_mv https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/18543
dc.language.none.fl_str_mv eng
dc.publisher.none.fl_str_mv Ordem dos Médicos
dc.rights.none.fl_str_mv http://purl.org/coar/access_right/c_abf2
dc.rights.rights.copyright.fl_str_mv https://creativecommons.org/licenses/by-nc/4.0
dc.source.none.fl_str_mv Acta Médica Portuguesa; Vol. 36 No. 3 (2023): March; 167-173
Acta Médica Portuguesa; Vol. 36 N.º 3 (2023): Março; 167-173
1646-0758
0870-399X
dc.subject.none.fl_str_mv Consensus
Multiple Sclerosis, Chronic Progressive/diagnosis
Portugal
Consenso
Esclerose Múltipla Crónica Progressiva/diagnóstico
Portugal
dc.title.fl_str_mv Consensus for the Early Identification of Secondary Progressive Multiple Sclerosis in Portugal: a Delphi Panel
Consenso Português para a Identificação Precoce de Esclerose Múltipla Secundária Progressiva: Painel Delphi
dc.type.none.fl_str_mv http://purl.org/coar/resource_type/c_6501
description Introduction: Multiple sclerosis is a disease with a heterogeneous evolution. The early identification of secondary progressive multiple sclerosis is a clinical challenge, which would benefit from the definition of biomarkers and diagnostic tools applicable in the transition phase from relapsing-remitting multiple sclerosis to secondary progressive multiple sclerosis. We aimed to reach a Portuguese national consensus on the monitoring of patients with multiple sclerosis and on the more relevant clinical variables for the early identification of its progression.Material and Methods: A Delphi panel which included eleven Portuguese Neurologists participated in two rounds of questions between July and August of 2021. In the first round, 39 questions which belonged to the functional, cognitive, imaging, biomarkers and additional evaluations were included. Questions for which no consensus was obtained in the first round (less than 80% of agreement), were appraised by the panel during the second round. Results: The response rate was 100% in both rounds and consensus was reached for a total of 33 questions (84.6%). Consensus was reached for monitoring time, evaluation scales and clinical variables such as the degree of brain atrophy and mobility reduction, changes suggestive of secondary progressive multiple sclerosis. Additionally, digital devices were considered tools with potential to identify disease progression. Most questions for which no consensus was obtained referred to the cognitive assessment and the remaining referred to both functional and imaging domains.Conclusion: Consensus was obtained for the determination of the monitorization interval and for most of the clinical variables. Most questions that did not reach consensus were related with the confirmation of progression taking into account only one test/domain, reinforcing the multifactorial nature of multiple sclerosis.
dirty 0
eu_rights_str_mv unknown
format article
id amp_0ff776959b2bbc85a3c7adfeebabec2f
identifier.url.fl_str_mv https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/18543
instacron_str om
institution Ordem dos Médicos
instname_str Ordem dos Médicos
language eng
network_acronym_str amp
network_name_str Acta Médica Portuguesa
oai_identifier_str oai:ojs.www.actamedicaportuguesa.com:article/18543
organization_str_mv urn:organizationAcronym:om
person_str_mv Sá, Maria José
Basílio, Carlos
Capela, Carlos
Cerqueira, José João
Mendes, Irene
Morganho, Armando
Correia de Sá, João
Salgado, Vasco
Martins Silva, Ana
Vale, José
Sousa, Lívia
publishDate 2023
publisher.none.fl_str_mv Ordem dos Médicos
reponame_str Acta Médica Portuguesa
repository_id_str urn:repositoryAcronym:amp
service_str_mv urn:repositoryAcronym:amp
spelling en-USConsensus for the Early Identification of Secondary Progressive Multiple Sclerosis in Portugal: a Delphi Panelpt-PTConsenso Português para a Identificação Precoce de Esclerose Múltipla Secundária Progressiva: Painel DelphiSá, Maria JoséBasílio, CarlosCapela, CarlosCerqueira, José JoãoMendes, IreneMorganho, ArmandoCorreia de Sá, JoãoSalgado, VascoMartins Silva, AnaVale, JoséSousa, LíviaConsensusMultiple Sclerosis, Chronic Progressive/diagnosisPortugalConsensoEsclerose Múltipla Crónica Progressiva/diagnósticoPortugalDireitos de Autor (c) 2023 Acta Médica Portuguesahttp://purl.org/coar/access_right/c_abf2https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/18543URLhttps://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/18543URLHasVersionhttps://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/18543/15035URLHasVersionhttps://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/18543/15036URLHasVersion2023-02-03en-USIntroduction: Multiple sclerosis is a disease with a heterogeneous evolution. The early identification of secondary progressive multiple sclerosis is a clinical challenge, which would benefit from the definition of biomarkers and diagnostic tools applicable in the transition phase from relapsing-remitting multiple sclerosis to secondary progressive multiple sclerosis. We aimed to reach a Portuguese national consensus on the monitoring of patients with multiple sclerosis and on the more relevant clinical variables for the early identification of its progression.Material and Methods: A Delphi panel which included eleven Portuguese Neurologists participated in two rounds of questions between July and August of 2021. In the first round, 39 questions which belonged to the functional, cognitive, imaging, biomarkers and additional evaluations were included. Questions for which no consensus was obtained in the first round (less than 80% of agreement), were appraised by the panel during the second round. Results: The response rate was 100% in both rounds and consensus was reached for a total of 33 questions (84.6%). Consensus was reached for monitoring time, evaluation scales and clinical variables such as the degree of brain atrophy and mobility reduction, changes suggestive of secondary progressive multiple sclerosis. Additionally, digital devices were considered tools with potential to identify disease progression. Most questions for which no consensus was obtained referred to the cognitive assessment and the remaining referred to both functional and imaging domains.Conclusion: Consensus was obtained for the determination of the monitorization interval and for most of the clinical variables. Most questions that did not reach consensus were related with the confirmation of progression taking into account only one test/domain, reinforcing the multifactorial nature of multiple sclerosis.pt-PTIntrodução: A esclerose múltipla é uma doença de evolução heterogénea. A identificação precoce da forma secundária progressiva é um desafio clínico, carecendo da definição de biomarcadores e ferramentas de diagnóstico aplicáveis na fase de transição da forma surto-remissão para a forma secundária progressiva. Este trabalho teve como objetivo estabelecer um consenso nacional português sobre a monitorização dos doentes e das variáveis clínicas mais relevantes para a identificação precoce da progressão da esclerose múltipla.Material e Métodos: Um painel Delphi constituído por 11 neurologistas portugueses respondeu a duas rondas de perguntas entre julho e agosto de 2021. Na primeira ronda foram incluídas 39 questões relacionadas com a avaliação funcional, cognitiva, imagiológica, de biomarcadores e outras, e na segunda, as questões para as quais não foi atingido consenso (menos de 80% de concordância) na primeira ronda voltaram a ser submetidas a avaliação pelo painel.Resultados: A taxa de resposta foi de 100% em ambas as rondas e 33 das 39 questões (84,6%) atingiram concordância. Foi atingido consenso relativamente ao tempo de monitorização dos doentes, às escalas de avaliação a empregar e a variáveis clínicas tais como o grau de atrofia cerebral ou redução da mobilidade, cuja alteração é sugestiva de esclerose múltipla secundária progressiva. Adicionalmente, os dispositivos digitais foram considerados ferramentas com potencial para identificar a progressão da doença. A maioria das questões para as quais não foi obtido consenso dizem respeito à avaliação cognitiva, estando as restantes inseridas nos domínios funcional e imagiológico.Conclusão: Foi obtido consenso para a determinação do intervalo de monitorização e para a maioria das variáveis clínicas. A maioria das questões sem consenso estavam relacionadas com a confirmação do diagnóstico de progressão tendo em conta apenas um teste/domínio, realçando a natureza multifatorial da esclerose múltipla.Ordem dos Médicosapplication/pdfapplication/pdfen-USActa Médica Portuguesa; Vol. 36 No. 3 (2023): March; 167-173pt-PTActa Médica Portuguesa; Vol. 36 N.º 3 (2023): Março; 167-1731646-07580870-399Xengjournal articlehttp://purl.org/coar/resource_type/c_6501literatureVoRhttp://purl.org/coar/version/c_970fb48d4fbd8a85https://creativecommons.org/licenses/by-nc/4.0
spellingShingle Consensus for the Early Identification of Secondary Progressive Multiple Sclerosis in Portugal: a Delphi Panel
Consensus for the Early Identification of Secondary Progressive Multiple Sclerosis in Portugal: a Delphi Panel
Sá, Maria José
Consensus
Multiple Sclerosis, Chronic Progressive/diagnosis
Portugal
Consenso
Esclerose Múltipla Crónica Progressiva/diagnóstico
Portugal
Sá, Maria José
Consensus
Multiple Sclerosis, Chronic Progressive/diagnosis
Portugal
Consenso
Esclerose Múltipla Crónica Progressiva/diagnóstico
Portugal
status NEW
status_str VoR
subject.fl_str_mv Consensus
Multiple Sclerosis, Chronic Progressive/diagnosis
Portugal
Consenso
Esclerose Múltipla Crónica Progressiva/diagnóstico
Portugal
title Consensus for the Early Identification of Secondary Progressive Multiple Sclerosis in Portugal: a Delphi Panel
title_full Consensus for the Early Identification of Secondary Progressive Multiple Sclerosis in Portugal: a Delphi Panel
title_fullStr Consensus for the Early Identification of Secondary Progressive Multiple Sclerosis in Portugal: a Delphi Panel
Consensus for the Early Identification of Secondary Progressive Multiple Sclerosis in Portugal: a Delphi Panel
title_full_unstemmed Consensus for the Early Identification of Secondary Progressive Multiple Sclerosis in Portugal: a Delphi Panel
Consensus for the Early Identification of Secondary Progressive Multiple Sclerosis in Portugal: a Delphi Panel
title_short Consensus for the Early Identification of Secondary Progressive Multiple Sclerosis in Portugal: a Delphi Panel
title_sort Consensus for the Early Identification of Secondary Progressive Multiple Sclerosis in Portugal: a Delphi Panel
topic Consensus
Multiple Sclerosis, Chronic Progressive/diagnosis
Portugal
Consenso
Esclerose Múltipla Crónica Progressiva/diagnóstico
Portugal
topic_facet Consensus
Multiple Sclerosis, Chronic Progressive/diagnosis
Portugal
Consenso
Esclerose Múltipla Crónica Progressiva/diagnóstico
Portugal
url https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/18543
visible 1